Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer’s disease
Authors:
- 7 November 2007
- journal article
- research article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 258 (2) , 124-128
Abstract
Alzheimer’s disease (AD) can be treated with inhibitors of the enzyme acetylcholinesterase (AChE). Recent pre-clinical and clinical studies gave evidence that AChE-inhibitors have neuroprotective effects and thereby a disease-modifying potential. The mechanism of this action is still discussed. In an animal model oral administration of an AChE-inhibitor lead to an increase of brain derived neurotrophic factor (BDNF) in hippocampus and cortex. Recent studies have found a decrease of BDNF in the serum and brain of AD patients with potentially consecutive lack of neurotrophic support and contribution to progressive neurodegeneration. BDNF serum concentrations were assessed by ELISA in 19 AD patients and 20 age-matched healthy controls at baseline and in the AD patients after 15 months of treatment with donepezil 10 mg per day (one patient received just 5 mg). Before treatment with donepezil we found in AD significantly decreased BDNF serum concentrations (19.2 ± 3.7 ng/ml) as compared to healthy controls (23.2 ± 6.0 ng/ml, P = 0.015). After 15 months of treatment the BDNF serum concentration increased significantly in the AD patients (23.6 ± 7.0 ng/ml, P = 0.001) showing no more difference to the healthy controls (P = 0.882). The results of the present study confirm data of prior investigations that a down-regulation of BDNF in serum and brain of AD patients seems to begin with the first clinical symptoms and to be persistent. A treatment with the AChE-inhibitor donepezil is accompanied with an increase of BDNF serum concentration in AD patients reaching the level of healthy controls. Thus, up-regulation of BDNF might be part of a neuroprotective effect of AChE-inhibitors. The molecular mechanism of this potentially disease-modifying mechanism of action of donepezil should be clarified.Keywords
This publication has 40 references indexed in Scilit:
- Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorderEuropean Archives of Psychiatry and Clinical Neuroscience, 2006
- Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in micePharmacology Biochemistry and Behavior, 2006
- The expanding role of BDNF: a therapeutic target for Alzheimer's disease?The Pharmacogenomics Journal, 2005
- Effect of treatment on serum brain–derived neurotrophic factor levels in depressed patientsEuropean Archives of Psychiatry and Clinical Neuroscience, 2005
- Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradationNature Medicine, 2005
- Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s diseaseMolecular Brain Research, 2003
- Role of the Immune System in the Pathogenesis, Prevention and Treatment of Alzheimer??s DiseaseDrugs & Aging, 2003
- Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and plateletsNeuroscience Letters, 2002
- Brain-derived neurotrophic factor in human plateletsBiochemical Pharmacology, 1997
- Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and functionJournal of Neuroscience, 1996